GlassScriptPhysician profile
Tiffany B Noyes
NPI 1225576267
$3,129.39
in general payments reported to CMS, 2019-2025
25 companies · $546 in 2025
The $546 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $629 · 2022: $544 · 2023: $625 · 2024: $786 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,107.34 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $370.75 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $240.13 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $222.20 | 2022-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $212.27 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $134.52 | 2021-2022 | |
| Braeburn INC. | $127.06 | 2024-2025 | Brixadi |
| Lundbeck LLC | $121.48 | 2022-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $98.87 | 2021-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $93.54 | 2022-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Indivior INC. | $66.34 | 2022-2024 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.10 | 2021-2024 | Caplyta |
| Merck Sharp & Dohme LLC | $59.70 | 2021 | |
| Pfizer INC. | $34.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.51 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $27.15 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.53 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.15 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $14.39 | 2025 | Cobenfy |
| Sanofi-Aventis U.S. LLC | $13.79 | 2021 | |
| Glaxosmithkline, LLC. | $13.57 | 2021 | |
| Eisai INC. | $13.00 | 2021 | |
| Axsome Therapeutics, INC. | $11.93 | 2025 | Auvelity |
| Lilly USA, LLC | $11.43 | 2021 | |
| Organon LLC | $7.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Noyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.